Published in Med Oncol on January 01, 2006
Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. Cancer Invest (2011) 0.84
Letter to editor. Re: "Effect of concomitant use of pentoxifylline (PTX) and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer". Med Oncol (2007) 0.75
Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma (2007) 2.55
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008) 2.42
Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol (2009) 1.60
Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets (2010) 1.48
Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis. Med Hypotheses (2004) 1.42
Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer (2007) 1.38
Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol (2010) 1.16
EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet (2010) 1.08
Association between common risk factors and molecular subtypes in breast cancer patients. Breast (2012) 1.06
Unusual location of hydatid cyst: soft tissue mass in the neck. Eur Arch Otorhinolaryngol (2006) 1.01
Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors. J Oral Maxillofac Surg (2006) 1.00
Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest (2007) 1.00
Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin (2013) 0.97
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev (2008) 0.96
Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod Pathol (2012) 0.95
Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother (2010) 0.95
Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin (2012) 0.94
Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol (2010) 0.94
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin (2013) 0.93
Metaplastic breast carcinoma: a heterogeneous disease. Asian Pac J Cancer Prev (2014) 0.92
Breast cancer subtypes and outcomes of central nervous system metastases. Breast (2011) 0.92
Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer (2010) 0.92
Hormone receptor status in patients with breast cancer and liver metastases treated with laser-induced intersititial thermotherapy. Radiology (2005) 0.91
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res (2007) 0.91
Anterior abdominal wall synovial sarcoma: a rare presentation. Am J Clin Oncol (2005) 0.91
Warfarin-induced skin necrosis and leukocytoclastic vasculitis in a patient with acquired protein C and protein S deficiency. Blood Coagul Fibrinolysis (2007) 0.90
Characteristics of breast cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc (2008) 0.90
Brain metastasis of cardiac myxoma: case report and review of the literature. J Neurooncol (2005) 0.90
Possible association between nanobacteria and malignant microcalcifications in breast cancer. Breast J (2006) 0.89
Trastuzumab in metastatic breast cancer after complete remission: How long is enough? Med Oncol (2015) 0.88
Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Med Oncol (2010) 0.88
Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol (2010) 0.87
Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Med Oncol (2013) 0.86
Ductal carcinoma in situ and bilateral atypical ductal hyperplasia in a 23-year-old man with gynecomastia. Am Surg (2011) 0.86
Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes. Med Oncol (2013) 0.86
Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother (2006) 0.85
Leptin and breast cancer: an overview. Med Oncol (2011) 0.84
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer (2004) 0.84
Preoperative Doppler sonography for prevention of perioperative stroke in head and neck cancer patients undergoing neck dissection: is it beneficial? J Clin Ultrasound (2007) 0.84
Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer. Med Oncol (2007) 0.84
Impact of inflammatory markers on the prognosis of patients with operable breast cancer. J BUON (2014) 0.84
Blood ABO groups and risk of breast cancer. Med Oncol (2010) 0.84
Herpes simplex type-2 encephalitis masked by diabetic ketoacidosis. J Natl Med Assoc (2005) 0.84
Treatment of recurrent cerebellar hemangioblastoma with external radiotherapy in a patient with von Hippel-Lindau disease: a case report and review of the literature. J Neurooncol (2005) 0.84
Isolated granulocytic sarcoma of the head and neck preceding acute myeloid leukemia. Am J Hematol (2004) 0.83
Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother (2009) 0.83
Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol (2005) 0.83
Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey. Med Oncol (2007) 0.82
Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol (2008) 0.82
Emerging drugs in metastatic breast cancer. Expert Opin Emerg Drugs (2009) 0.82
The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration. Curr Med Res Opin (2014) 0.82
Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Curr Med Res Opin (2015) 0.81
Extramedullary plasmacytoma of nasopharynx and larynx: synchronous presentation. Am J Hematol (2004) 0.81
Possible mechanisms behind taxane-anthracycline sequencing. Lancet Oncol (2010) 0.81
Embryonal rhabdomyosarcoma of the larynx. Otolaryngol Head Neck Surg (2005) 0.81
Brucella glomerulonephritis: case report and review of the literature. South Med J (2005) 0.81
Association between obesity and multiple myeloma in postmenopausal women may be attributed to increased aromatization of androgen in adipose tissue. Med Hypotheses (2005) 0.81
Fluorouracil-induced neurotoxicity presenting with generalized tonic-clonic seizure. Ann Pharmacother (2004) 0.81
Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat (2007) 0.80
Global warming may increase the incidence and geographic range of Crimean-Congo Hemorrhagic Fever. Med Hypotheses (2006) 0.80
Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Med Oncol (2005) 0.80
Systemic anaphylactic reaction following intrathecal administration of methotrexate in adult patient with primary central nervous system lymphoma. Am J Hematol (2004) 0.80
Medulloblastoma/primitive neuroectodermal tumor in adults: prognostic factors and treatment results: a single-center experience from Turkey. Med Oncol (2007) 0.80
Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer (2006) 0.80
A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors. J BUON (2014) 0.80
Two important determinants may play a role in the success of the FinHer Trial. J Clin Oncol (2010) 0.79
Prophylactic human papilloma virus vaccines for cervical cancer may also prevent development of breast and oropharyngeal cancers in women. Med Hypotheses (2006) 0.79
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. Expert Opin Pharmacother (2014) 0.79
Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. Med Oncol (2012) 0.79
Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. JAMA (2008) 0.79
Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors. Breast Cancer Res Treat (2007) 0.79
Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin (2013) 0.79
The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON (2015) 0.79
Granulocytic sarcoma of the urinary bladder. Am J Hematol (2004) 0.79
Association of breast cancer subtypes and body mass index. Tumori (2013) 0.79
Invasive papillary carcinoma of the breast: an overview of twenty-four cases. Am Surg (2012) 0.79
Can all beta blockers improve the breast cancer survival? Breast (2011) 0.79
Lymphatic and capillary invasion patterns in triple negative breast cancer. Am Surg (2012) 0.79
Possible role of CXCR4-mediated chemotaxis in breast cancer patients with central nervous system metastases. Breast Cancer Res Treat (2005) 0.79
Re: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst (2005) 0.78
Anal tumor diagnosed after the recovery of Fournier gangrene. Dig Dis Sci (2006) 0.78
Thymic epithelial neoplasia: a study of 58 cases. Med Oncol (2007) 0.78
Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report. Eur J Clin Pharmacol (2004) 0.78
Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response. Tumori (2012) 0.78
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer (2005) 0.78
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer. Lung Cancer (2005) 0.78
The effect of obesity on recurrence pattern in early breast cancer patients. J BUON (2015) 0.78
The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. J BUON (2015) 0.78
The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas. Med Oncol (2007) 0.78
HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. Lung Cancer (2005) 0.78
Frequency of HCV infection in renal cell carcinoma patients. Med Oncol (2011) 0.78
Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients. Breast J (2013) 0.78
Pure mucinous breast carcinoma with lung metastasis in a young male patient. Am Surg (2010) 0.78
Nanobacteria and breast implant capsule contracture and calcification: a hypothesis. Aesthetic Plast Surg (2005) 0.78